Результаты поиска

An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.

Oncologic patients are subjected to four major treatment types: surgery, radiotherapy, chemotherapy, and immunotherapy. All nonsurgical forms of cancer management are known to potentially violate the structural and functional integrity of the cardiovascular system. The prevalence and severity of cardiotoxicity and vascular abnormalities led to the emergence of a clinical subdiscipline, called cardiooncology. This relatively new, but rapidly expanding area of knowledge, primarily focuses on clinical observations linking the adverse effects of cancer therapy with deteriorated quality of life of

Совпадение в полном тексте источника
… P waves) [ 251 ] Cyclophosphamide ALL, breast cancer, CLL, Ewing sarcoma, HL, NHL, multiple myeloma, SCLC [ 15 ] Arrhythmias, chest pain, pleural and pericardial effusions, myocarditis, pericarditis, myocardial infarction, cardiac tamponade, HF, ECG changes (loss of QRS voltage) [ 251 , 503 , 506 ] Ifosfamide … waves) [ 251 ] Cyclophosphamide | ALL, breast cancer, CLL, Ewing sarcoma, HL, NHL, multiple myeloma, SCLC [ 15 ] | Arrhythmias, chest pain, pleural and pericardial effusions, myocarditis, pericarditis, myocardial infarction, cardiac tamponade, HF, ECG changes (loss of QRS voltage) [ 251 , 503 , 506 ] Ifosfamide …

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

Over the past decade, chronic lymphocytic leukaemia (CLL) treatment has shifted from chemoimmunotherapy to targeted oral agents, predominantly Bruton's tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor venetoclax. These therapies have significantly improved outcomes and are now established as first-line treatment options. However, CLL remains incurable, and resistance or intolerance to both drug classes (double-refractory disease) is an emerging challenge. This has driven the development of novel therapeutic strategies, including non-covalent BTKis such as pirtobrutinib and nemtabruti

Совпадение в полном тексте источника
… The drug was studied alone or in combination with itacitinib (Janus kinase 1 inhibitor) or CIT with rituximab, ifosfamide, carboplatin, and etoposide in patients with RR B-cell malignancies (# NCT02018861 ) [ 113 ]. …

Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Cancer patients experience symptoms and adverse effects of treatments that may last even after the end of treatments. Exercise is a safe, non-pharmacological and cost-effective therapy that can provide several health benefits in cancer patient and survivors, reducing cancer symptoms and cancer treatment side effects. The purpose of this review is to describe how the physical exercise is capable to reduce cancer symptoms and cancer treatment side effects. We realized a pragmatic classification of symptoms, dividing them into physical, psychological and psycho-physical aspects. For each symptom

Совпадение в полном тексте источника
… Some chemotherapeutic agents such as platinum derived agents and ifosfamide cause nephrotoxicity, resulting in alteration of the calcium regulation mechanisms through reduction of Vitamin D [ 5 ]. What are the possible therapies for bone metastasis and bone loss? …

Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.

Malignant bone tumors, which are difficult to treat with current clinical strategies, originate from bone tissues and can be classified into primary and secondary types. Due to the specificity of the bone microenvironment, the results of traditional means of treating bone tumors are often unsatisfactory, so there is an urgent need to develop new treatments for malignant bone tumors. Recently, nanoparticle-based approaches have shown great potential in diagnosis and treatment. Nanoparticles (NPs) have gained significant attention due to their versatility, making them highly suitable for applica

Совпадение в полном тексте источника
… Another single-arm, single-center, open-label clinical study included 25 patients with advanced metastatic STS to evaluate the clinical efficacy and safety of PLD in combination with ifosfamide (IFO). …

Translational Strategies to Target Metastatic Bone Disease.

Metastatic bone disease is a common and devastating complication to cancer, confounding treatments and recovery efforts and presenting a significant barrier to de-escalating the adverse outcomes associated with disease progression. Despite significant advances in the field, bone metastases remain presently incurable and contribute heavily to cancer-associated morbidity and mortality. Mechanisms associated with metastatic bone disease perpetuation and paralleled disruption of bone remodeling are highlighted to convey how they provide the foundation for therapeutic targets to stem disease escala

Совпадение в полном тексте источника
… Ultimately, defective bone mineralization is compounded by toxic effects on the ovaries, which contributes to hypogonadism leading to premature menopause, and kidney failure, as observed with ifosfamide ( Figure 2 B). …

Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.

Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its' very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of num

Совпадение в полном тексте источника
… Osteosarcoma (OS) patients are generally treated with combination chemotherapy comprising cisplatin, doxorubicin, and high-dose methotrexate, with addition of ifosfamide [ 130 ]. However, a fundamental problem is the long duration of treatment, which leads to undesirable effects [ 118 ]. …

Infections in Recipients of Hematopoietic Stem Cell Transplants

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience.

Metronomic chemotherapy, continuous and dose-dense administration of chemotherapeutic drugs with lowered doses, is being evaluated for substituting, augmenting, or appending conventional maximum tolerated dose regimens, with preclinical and clinical studies for the past few decades. To date, the principle mechanisms of its action include impeding tumoral angiogenesis and modulation of hosts' immune system, affecting directly tumor cells, their progenitors, and neighboring stromal cells. Its better toxicity profile, lower cost, and easier use are main advantages over conventional therapies. The

Совпадение в полном тексте источника
… Metronomic chemotherapy is also a feasible instrument for treating sarcomas, as angiogenesis is a rational target to control the disease and the typical population bearing the cancer can possibly be debilitated for standard doxorubicin or ifosfamide based treatment, so administrating a more palliative …

Dermatologic conditions in women receiving systemic cancer therapy.

As advances in cancer therapies have improved cancer-related survival, novel therapeutics have also introduced a variety of dermatologic toxicities, and an increased number of patients are living with these sequalae. Women with cancer in particular experience a spectrum of dermatologic conditions that affect their skin, hair, nail, and mucosal surfaces. Studies have shown that these toxic effects can significantly affect quality of life and alter a woman's self-image, cultural identity, femininity, sexuality, and mental health. In severe instances, dermatologic toxicities may even disrupt canc

Совпадение в полном тексте источника
… Vincristine | ALL, AML, Hodgkin's disease, neuroblastoma, small cell lung | Vinblastine | Hodgkin's disease, non-small cell lung, bladder, brain, melanoma, testicular Alkylating agents | Cyclophosphamide | Lymphomas, multiple myeloma, leukemia, ovarian, breast, small cell lung, neuroblastoma, sarcoma | Ifosfamide …

Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.

The prevalence of cancers has actually increased during the last few decades, affecting almost all human societies. Despite progress in therapeutic protocols, cancer is still the main cause of global human mortality. Although the advancement of modern immunotherapeutic approaches can increase the survival rate of cancer patients, new modalities are essential for improved therapeutic outcomes. Extracellular vesicles (EVs) are nanosized particles and are used for cell-free approaches instead of direct whole cell-based administration. It has been thought that EVs can reduce the risks and side eff

Mechanisms of Chemotherapy-Induced Neurotoxicity.

Since the first clinical trials conducted after World War II, chemotherapeutic drugs have been extensively used in the clinic as the main cancer treatment either alone or as an adjuvant therapy before and after surgery. Although the use of chemotherapeutic drugs improved the survival of cancer patients, these drugs are notorious for causing many severe side effects that significantly reduce the efficacy of anti-cancer treatment and patients' quality of life. Many widely used chemotherapy drugs including platinum-based agents, taxanes, vinca alkaloids, proteasome inhibitors, and thalidomide ana

Совпадение в полном тексте источника
… dacarbazine, mechlorethamine, streptozotocin Moderate (30–90%) | Cytotoxic agents | Arsenic trioxide, azacytidine, bendamustine, busulfan, carboplatin, clofarabine, CP (<1,500 mg/m 2 ), cytarabine (>1,000 mg/m 2 ), daunorubicin, daunorubicin + cytarabine liposome, doxorubicin, epirubicin, idarubicin, ifosfamide …

Hematopoietic Tumors

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Other drugs that have documented activity are often considered second-line agents and include rabacfosadine (Tanovea-CA1), lomustine, vinblastine, actinomycin-D, mitoxantrone, mustargen, chlorambucil, methotrexate, dacarbazine (DTIC), 9-aminocamptothecin, ifosfamide, cytosine arabinoside, procarbazine … Of these, cytosine arabinoside, 263 ifosfamide, 264 bleomycin, 265 and gemcitabine 266 appear to have minimal activity. With the exception of DOX, single-agent induction therapy does not typically result in durable remission durations compared with standard combination protocols. …

Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity.

Introduction: The toxicity of arsenic is widely recognized globally, mainly harming human health by polluting water, soil, and food. However, its formulations can also be used for the clinical treatment of diseases such as leukemia and tumors. Arsenic has been used as a drug in China for over 2,400 years, with examples such as the arsenic-containing drug realgar mentioned in Shennong's Herbal Classic. We have reviewed references on arsenic over the past thirty years and found that research has mainly focused on clinical, pharmacological, and toxicological aspects. Results and Discussion: The f

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.

The paradigm of pediatric drug development has been evolving in a "carrot-and-stick"-based tactic to address population-specific issues. However, the off-label prescription of adult medicines to pediatric patients remains a feature of clinical practice, which may compromise the age-appropriate evaluation of treatments. Therefore, the United States and the European Pediatric Formulation Initiative have recommended applying nanotechnology-based delivery systems to tackle some of these challenges, particularly applying inorganic, polymeric, and lipid-based nanoparticles. Connected with these, adv

Совпадение в полном тексте источника
… Recruiting | Acute Leukemia | Mitoxantrone liposome anti-thymocyte globulin NCT04293562 | III | Recruiting | Acute Myeloid Leukemia | Liposome-encapsulated daunorubicin-cytarabine, among others NCT04606108 | II | Recruiting | Soft Tissue Sarcoma | Camrelizumab in combination with liposome doxorubicin and ifosfamide …

Резюме докладов 2017 Ежегодное совещание Общества общей внутренней медицины.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.

BackgroundChimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematological malignancies, yet its application in solid tumors remains constrained by unique biological and logistical barriers.ObjectiveThis review critically examines the evolving landscape of CAR T-cell therapy in solid malignancies, with a focus on antigen heterogeneity, the immunosuppressive tumor microenvironment, and risks of on-target, off-tumor toxicity.MethodsWe outline recent advances in CAR engineering, including co-stimulatory optimization, dual- and multi-antigen targeting, armored CARs, an

Совпадение в полном тексте источника
… In the non-randomized Phase II SPEARHEAD-1 trial ( NCT04044768 ), patients with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma with MAGE-A4 expression, and who had been previously treated with at least one line of anthracycline-containing or ifosfamide-containing chemotherapy …

The prince and the pauper. A tale of anticancer targeted agents.

Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in 2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently are in the interphase of two treatment eras. The so-called pregenomic therapy which names the traditional cancer drugs, mainly cytotoxic drug types, and post-genomic era-type drugs referring to rationally-based designed. Although there are successful examples of this newer drug discovery approach, most target-specific agents only provide small gains in symptom control and/or survival, whereas others have consiste

Совпадение в полном тексте источника
… Increased responses and survival were also observed in a trial performed in 72 patients with non-small-cell lung cancer randomized to vindesine-ifosfamide-mesna plus minus verapamil [ 31 ]. …

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.

Over the course of several decades, anticancer treatment with chemotherapy drugs for lung cancer has not changed significantly. Unfortunately, this treatment prolongs the patient's life only by a few months, causing many side effects in the human body. It has also been proven that drugs such as Cisplatin, Carboplatin, Oxaliplatin and others can react with other substances containing an aromatic ring in which the nitrogen atom has a free electron group in its structure. Thus, such structures may have a competitive effect on the nucleobases of DNA. Therefore, scientists are looking not only for

Совпадение в полном тексте источника
… Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma . J Clin Oncol . 1991 ; 9 ( 9 ): 1549 – 1555 . doi: 10.1200/JCO.1991.9.9.1549 1651992 40. Ghosh SC . The first metal based anticancer drug . …

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives.

Immunotherapy has achieved remarkable clinical success in certain cancers, particularly through adoptive cell therapy (ACT), where T cell engineering with chimeric antigen receptor (CAR) has driven major clinical breakthroughs in the treatment of hematologic malignancies. However, efficacy against solid tumors remains limited due to multiple barriers, including the scarcity of tumor-specific antigens, antigen heterogeneity, immunosuppressive tumor microenvironment, and physical obstruction of T cell infiltration by dense extracellular matrix. Nanoparticle (NP)-based approaches can overcome the

Совпадение в полном тексте источника
… Patients receive chemotherapy (doxorubicin and/or ifosfamide) and a lymphodepleting regimen (fludarabine and cyclophosphamide) prior to T cell infusion. While TCR T cells offer certain biological advantages, research and clinical development have focused on CAR T cells. …

Targeted therapies in pediatric oncology: A start.

The treatment of cancers was revolutionized by the use of combination "conventional" chemotherapy, first in children, during the 20th century. That foundation of therapy, while having achieved significant advances in survival, has reached its limits. Innovations in targeted therapies are now building upon that foundation to further improve outcomes in pediatric oncology. These targeted agents are designed to narrowly utilize specific biologic processes for greater efficacy and optimally fewer generalized toxicities. I will provide an overview of the current spectrum of targeted therapies avail

Совпадение в полном тексте источника
… A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group Pediatr. …